

# MOLECULAR THERAPY

*The Journal of the American  
Society of Gene Therapy*

## Editor-in-Chief

Inder M. Verma

## Editor

Fintan R. Steele

## Associate Editors

Malcolm Brenner  
Leaf Huang  
Elizabeth G. Nabel  
Irving L. Weissman  
James M. Wilson

## Editorial Board

Estuardo Aguilar-Cordova  
Jean-Paul Behr  
R. Michael Blaese  
Helen M. Blau  
David Bodine  
Xandra O. Breakefield  
Hermann Bujard  
Jeffrey Chamberlain  
Seng H. Cheng  
Charles Coutelle  
Ronald G. Crystal  
David T. Curiel  
Olivier Danos  
John E. Dick  
Victor J. Dzau  
Philip L. Felgner  
Theodore Friedmann  
Fred H. Gage  
Joseph C. Glorioso  
Philip Greenberg  
Markus Grompe  
Stephen D. Hauschka  
Katherine High  
Jeffrey M. Isner  
Yasufumi Kaneda  
Mark A. Kay  
Susan Kingsman  
Donald B. Kohn  
Jeffrey M. Leiden  
Kam Leong  
Margaret A. Liu  
Dusty Miller  
Richard C. Mulligan  
Nicholas Muzyczka  
Gary J. Nabel  
Luigi Naldini  
Arthur W. Nienhuis  
Garry P. Nolan  
Drew Pardoll  
Michel Perricaudet  
John J. Rossi  
David Russell  
Stephen J. Russell  
Michel Sadelain  
Cyrus R. Safinya  
Izumu Saito  
R. Jude Samulski  
Alan E. Smith  
George Stamatoyannopoulos  
Frank Szoka, Jr.  
Didier Trono  
Dinko Valerio  
Jean-Michel Vos  
Matthew D. Weitzman  
David A. Williams  
Jon A. Wolff  
Savio L. C. Woo

## Gene Therapy: Beyond 2000

"Success in gene therapy, at last" (*New York Times* editorial headline, April 30, 2000). Such heartening news is a joy to behold for practitioners of the science of gene therapy. Ever since the news of the death of 18-year-old Jessie Gelsinger 9 months ago, the field of gene therapy has witnessed an unprecedented barrage of bad publicity. Sweeping statements like "The end of a promising medical technology," "A promise unfulfilled," or "Undue hype leads to premature end" were the rule rather than the exception. The general condemnation of the field was not restricted to the news media; many prominent scientists and research establishments also expressed deep concern. Interestingly, the commercial sector involved in gene therapy reacted to the adverse publicity with indifference and even defiance on Wall Street.

The Senate health subcommittee had a hearing on gene therapy safety and risks. A follow-up is in the offing in the coming weeks. Additionally, the House of representatives is planning to have a hearing on this subject, and both the Secretary of Health and Human Services and the President have commented on the adverse effects of gene therapy. Not surprisingly, there has been a flurry of activity at the NIH and the FDA with very active participation from the American Society of Gene Therapy. The gene therapy community is now bracing itself for new regulations and requirements for clinical trials. We hope that these new guidelines will be sensible and practical and not adversely affect the current steady progress in the field of gene therapy.

The basic concept of gene therapy has always been very simple—introduce a gene whose product has the ability to either cure or slow down the progression of disease. The recent paper by Alain Fischer and colleagues from Paris (*Science* 288: 669–672, 2000) has brought this simple concept to reality. Two infants, aged 11 and 8 months, who suffered from severe combined immunodeficiency (SCID)-XI disease have been successfully treated for over 270 days. A third child treated at 1 month of age is at home without any other therapy for over 4 months.

SCID-XI is an x-linked inherited disorder characterized by an early block in T and natural killer (NK) lymphocyte differentiation due to mutations of the gene encoding the  $\gamma_c$  cytokine receptor subunit common to IL-2, -4, -7, -9, and -15 receptors. A mutation in the  $\gamma_c$  subunit leads to disruption of signals for growth, survival, and differentiation to lymphoid progenitor cells. CD34<sup>+</sup> cells from the patient were transduced *ex vivo* with a recombinant murine leukemia viral vector containing the  $\gamma_c$  receptor gene and infused back into the young patients without any chemoablation. After 10 months  $\gamma_c$  transgene expression in T and NK cells was detected in both patients, but more importantly T, B, and NK cell counts and function were comparable to those of age-matched controls. To all appearances, the recipients are clinically cured, and the fantastic promise of gene therapy is realized!

Several caveats clearly remain—(i) only 10 months of data are available, and expression of the transgene driven by LTRs may cease; (ii) a very small number of patients have been treated to date; and (iii) as the authors point out, this success may be due to strong positive selective pressure provided to the corrected lymphoid progenitors. What is particularly gratifying, however, is the care and caution exercised by these investigators, involving years of experimentation in mice and dogs and incremental use of the technical advances in the field.

The news of successful gene therapy in SCID-XI patients was preceded with guarded optimism about the success in two hemophilia patients receiving human factor IX genes delivered by adeno-associated viral vectors (Kay *et al.*, *Nat. Genet.* 24: 257–261, 2000). Although there is much to cheer about in these early successes, we must also remind ourselves that "a single sparrow does not make spring."

Inder M. Verma

Editor-in-Chief, *Molecular Therapy*

This Editorial is identified by doi:10.1006/mthe.2000.0084.